Immunic Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Immunic Therapeutics's estimated annual revenue is currently $16.6M per year.
- Immunic Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Immunic Therapeutics has 107 Employees.
- Immunic Therapeutics grew their employee count by 20% last year.
Immunic Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, President and Director | Reveal Email/Phone |
2 | VP, Program Management & Clinical Development Operations | Reveal Email/Phone |
3 | Head Intellectual Property | Reveal Email/Phone |
4 | Head Investor Relations and Communications | Reveal Email/Phone |
5 | Head Preclinical Development | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Director Early Clinical Development | Reveal Email/Phone |
9 | Co-Founder & Chief Medical Officer | Reveal Email/Phone |
10 | Executive Assistant / Office Manager | Reveal Email/Phone |
Immunic Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Immunic Therapeutics?
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis.
keywords:N/A
N/A
Total Funding
107
Number of Employees
$16.6M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immunic Therapeutics News
2022-04-19 - Primary Sclerosing Cholangitis Pipeline: Therapeutic ...
The major Primary Sclerosing Cholangitis companies include Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics,...
Other Companies in New York City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $31M | 107 | -3% | N/A |
#2 | $17.9M | 107 | 45% | N/A |
#3 | $18.2M | 107 | 9% | N/A |
#4 | $29.2M | 108 | 16% | N/A |
#5 | $27.6M | 110 | 25% | N/A |